Beneficial therapeutic effects of Nigella sativa and/or Zingiber officinale in HCV patients in Egypt
- PMID: 27298610
- PMCID: PMC4904745
Beneficial therapeutic effects of Nigella sativa and/or Zingiber officinale in HCV patients in Egypt
Abstract
Hepatitis C is a major global health burden and Egypt has the highest prevalence of hepatitis C virus (HCV) worldwide. The current study was designed to evaluate the beneficial therapeutic effects of ethanolic extracts of Nigella sativa, Zingiber officinale and their mixture in Egyptian HCV patients. Sixty volunteer patients with proven HCV and fifteen age matched healthy subjects were included in this study. Exclusion criteria included patients on interferon alpha (IFN-α) therapy, infection with hepatitis B virus, drug-induced liver diseases, advanced cirrhosis, hepatocellular carcinoma (HCC) or other malignancies, blood picture abnormalities and major severe illness. Liver function enzymes, albumin, total bilirubin, prothrombin time and concentration, international normalized ratio, alpha fetoprotein and viral load were all assessed at baseline and at the end of the study. Ethanolic extracts of Nigella sativa and Zingiber officinale were prepared and formulated into gelatinous capsules, each containing 500 mg of Nigella sativa and/or Zingiber officinale. Clinical response and incidence of adverse drug reactions were assessed initially, periodically, and at the end of the study. Both extracts as well as their mixture significantly ameliorated the altered viral load, alpha fetoprotein, liver function parameters; with more potent effect for the combined therapy. In conclusion, administration of Nigella sativa and/or Zingiber officinale ethanolic extracts to HCV patients exhibited potential therapeutic benefits via decreasing viral load and alleviating the altered liver function, with more potent effect offered by the mixture.
Keywords: Hepatitis C; Nigella sativa; Zingiber officinale; viral load.
Figures
Similar articles
-
Effects of Nigella sativa on outcome of hepatitis C in Egypt.World J Gastroenterol. 2013 Apr 28;19(16):2529-36. doi: 10.3748/wjg.v19.i16.2529. World J Gastroenterol. 2013. PMID: 23674855 Free PMC article. Clinical Trial.
-
The potential therapeutic effect of Nigella sativa and Zingiber officinale extracts versus Nitazoxanide drug against experimentally induced cryptosporidiosis in laboratory mice.J Parasit Dis. 2023 Jun;47(2):329-339. doi: 10.1007/s12639-023-01572-z. Epub 2023 Mar 25. J Parasit Dis. 2023. PMID: 37193490 Free PMC article.
-
Evaluation of the Anticancer Activity of Phytomolecules Conjugated Gold Nanoparticles Synthesized by Aqueous Extracts of Zingiber officinale (Ginger) and Nigella sativa L. Seeds (Black Cumin).Materials (Basel). 2021 Jun 18;14(12):3368. doi: 10.3390/ma14123368. Materials (Basel). 2021. PMID: 34206999 Free PMC article.
-
Burden of pediatric hepatitis C.World J Gastroenterol. 2013 Nov 28;19(44):7880-8. doi: 10.3748/wjg.v19.i44.7880. World J Gastroenterol. 2013. PMID: 24307782 Free PMC article. Review.
-
Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.Cochrane Database Syst Rev. 2017 Mar 13;3(3):CD011644. doi: 10.1002/14651858.CD011644.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2018 Dec 03;12:CD011644. doi: 10.1002/14651858.CD011644.pub3. PMID: 28285495 Free PMC article. Updated. Review.
Cited by
-
The efficacy and safety of ginger (Zingiber officinale) rhizome extract in outpatients with COVID-19: A randomized double-blind placebo-control clinical trial.Medicine (Baltimore). 2024 May 31;103(22):e38289. doi: 10.1097/MD.0000000000038289. Medicine (Baltimore). 2024. PMID: 39259072 Free PMC article. Clinical Trial.
-
Identification, validation and quantification of thymoquinone in conjunction with assessment of bioactive possessions and GC-MS profiling of pharmaceutically valuable crop Nigella (Nigella sativa L.) varieties.PeerJ. 2024 Mar 29;12:e17177. doi: 10.7717/peerj.17177. eCollection 2024. PeerJ. 2024. PMID: 38563005 Free PMC article.
-
Effect of Nigella sativa on Selected Gastrointestinal Diseases.Curr Issues Mol Biol. 2023 Apr 3;45(4):3016-3034. doi: 10.3390/cimb45040198. Curr Issues Mol Biol. 2023. PMID: 37185722 Free PMC article. Review.
-
Ethnobotanical Survey of Medicinal Plants Used in the Treatment of COVID-19 and Related Respiratory Infections in Ogbomosho South and North Local Government Areas, Oyo State, Nigeria.Plants (Basel). 2022 Oct 10;11(19):2667. doi: 10.3390/plants11192667. Plants (Basel). 2022. PMID: 36235532 Free PMC article.
-
The effect of Nigella sativa on TAC and MDA in obese and overweight women: secondary analysis of a crossover, double blind, randomized clinical trial.J Diabetes Metab Disord. 2022 Feb 7;21(1):171-179. doi: 10.1007/s40200-021-00954-5. eCollection 2022 Jun. J Diabetes Metab Disord. 2022. PMID: 35673509 Free PMC article.
References
-
- Al-Gaby AM. Amino acid composition and biological effects of supplementing broad bean and corn proteins with Nigella sativa (black cumin) cake protein. Nahrung. 1998;42:290–294. - PubMed
-
- Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003;17:299–305. - PubMed
-
- Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol. 2008;46:409–20. - PubMed
-
- Al-Naggar TB, Gómez-Serranillos MP, Carretero ME, Villar AM. Neuropharmacological activity of Nigella sativa L. extracts. J Ethnopharmacol. 2003;88:63–68. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources